1. Home
  2. PMCB vs DFNS Comparison

PMCB vs DFNS Comparison

Compare PMCB & DFNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.42

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Logo T3 Defense Inc. Common Stock

DFNS

T3 Defense Inc. Common Stock

HOLD

Current Price

$2.40

Market Cap

4.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMCB
DFNS
Founded
1996
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
4.2M
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
PMCB
DFNS
Price
$0.42
$2.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $65.00
AVG Volume (30 Days)
97.6K
★ 555.2K
Earning Date
12-17-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 261.46
EPS
★ N/A
N/A
Revenue
N/A
★ $5,913,461.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$33.09
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.30
$1.75
52 Week High
$1.51
$335.00

Technical Indicators

Market Signals
Indicator
PMCB
DFNS
Relative Strength Index (RSI) 61.27 28.60
Support Level $0.32 N/A
Resistance Level $0.77 $7.36
Average True Range (ATR) 0.06 0.44
MACD 0.01 0.08
Stochastic Oscillator 91.64 20.25

Price Performance

Historical Comparison
PMCB
DFNS

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

About DFNS T3 Defense Inc. Common Stock

T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. The company operates as a strategic platform, building a portfolio of mission-critical suppliers and technology companies. Its portfolio includes businesses involved in defense and aerospace technologies, such as AI software, unmanned aerial systems, electro-mechanical manufacturing, and motion control systems, as well as activities in technology distribution, licensing, and defense infrastructure development through joint ventures.

Share on Social Networks: